.Pharmacolibrary.Drugs.ATC.L.L04AJ06 .Pharmacolibrary.Drugs.ATC.L.L04AJ06| name: | Zilucoplan |
| ATC code: | L04AJ06 | route: | subcutaneous |
| n-compartments | 1 |
Zilucoplan is a synthetic macrocyclic peptide complement C5 inhibitor used for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive. It works by preventing complement-mediated damage at the neuromuscular junction. Zilucoplan is approved for clinical use as of 2023.
Pharmacokinetic parameters reported for adult patients with generalized myasthenia gravis after subcutaneous administration.
Howard, JF, et al., & Wiendl, H (2021). Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert opinion on investigational drugs 30(5) 483–493. DOI:10.1080/13543784.2021.1897567 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33792453